Program
linaprazan glurate
Also written as “X842”, “Linaprazan glurate” and “Single ascending dose of X842”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis · Esophagitis, Peptic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cinclus Pharma Holding AB | 81 open or running | phase 3since Jun 17, 2025 | Mar 1, 2017 | Nov 30, 2026phase 1 · NCT05469854 |
| Jiangsu Sinorda Biomedicine | 50 open or running | phase 3since Jul 14, 2025 | Feb 7, 2020 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2017First study: early phase 1 study in Gastroesophageal RefluxNew to Cinclus Pharma Holding ABCinclus Pharma Holding AB · NCT03105375 · 39 enrolled · Sweden
- Feb 7, 2020Jiangsu Sinorda Biomedicine's first study: phase 1 study in EsophagitisNew to Jiangsu Sinorda BiomedicineJiangsu Sinorda Biomedicine · NCT04293965 · 80 enrolled · China
- Aug 26, 2020Phase 2 study in Esophagitis, PepticJiangsu Sinorda Biomedicine · NCT04531475 · 90 enrolled · China
- Sep 14, 2021Phase 2 study in Erosive EsophagitisCinclus Pharma Holding AB · NCT05055128 · 248 enrolled · United States, Bulgaria, Czechia and more
- Jul 15, 2022Phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05469854 · 121 planned · Sweden
- Nov 16, 20222 phase 1 studiesCinclus Pharma Holding AB · NCT05627518, NCT05633147
- Jan 2, 2023Phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05742984 · 75 enrolled · Slovenia
- Jun 17, 2025Phase 3 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT07037875 · 523 enrolled · Bulgaria, Czechia, Georgia and more
- Jul 14, 2025Phase 1 study in Gastroesophageal RefluxJiangsu Sinorda Biomedicine · NCT07107672 · 6 enrolled · China
- Jul 14, 2025Phase 3 study in Esophagitis, PepticJiangsu Sinorda Biomedicine · NCT07079540 · 380 enrolled · China
- Sep 4, 2025Phase 1 study in Healthy VolunteersJiangsu Sinorda Biomedicine · NCT07294846 · 56 enrolled · China
- Dec 19, 2025Phase 3 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT07313774
Ahead
- Nov 30, 2026Primary completion: phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05469854
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07313774Gastroesophageal Reflux | 3 | Withdrawn | Cinclus Pharma Holding AB | Sep 2028 | 0 |
| NCT07294846Healthy Volunteers · China | 1 | Completed | Jiangsu Sinorda Biomedicine | Dec 15, 2025 | 56 |
| NCT07107672Gastroesophageal Reflux · China | 1 | Completed | Jiangsu Sinorda Biomedicine | Jul 7, 2022 | 6 |
| NCT07079540Esophagitis, Peptic · China | 3 | Completed | Jiangsu Sinorda Biomedicine | Jul 27, 2022 | 380 |
| NCT07037875Gastroesophageal Reflux · Bulgaria, Czechia, Georgia and more | 3 | Completed | Cinclus Pharma Holding AB | Sep 28, 2026 | 523 |
| NCT05742984Gastroesophageal Reflux · Slovenia | 1 | Completed | Cinclus Pharma Holding AB | Mar 24, 2023 | 75 |
| NCT05633147Safety Issues · Sweden | 1 | Completed | Cinclus Pharma Holding AB | May 30, 2023 | 35 |
| NCT05627518Safety · Slovenia | 1 | Completed | Cinclus Pharma Holding AB | Dec 30, 2022 | 67 |
| NCT05469854Gastroesophageal Reflux · Sweden | 1 | Recruiting | Cinclus Pharma Holding AB | Nov 30, 2026 | 121 |
| NCT05055128Erosive Esophagitis · United States, Bulgaria, Czechia and more | 2 | Completed | Cinclus Pharma Holding AB | Sep 1, 2022 | 248 |
| NCT04531475Esophagitis, Peptic · China | 2 | Completed | Jiangsu Sinorda Biomedicine | Oct 24, 2020 | 90 |
| NCT04293965Esophagitis · China | 1 | Completed | Jiangsu Sinorda Biomedicine | Sep 4, 2019 | 80 |
| NCT03105375Gastroesophageal Reflux · Sweden | Early 1 | Completed | Cinclus Pharma Holding AB | Oct 12, 2017 | 39 |
How it is read
Names in the registry
- “X842”, 3 entries
- “Linaprazan glurate”, 3 entries
- “Single ascending dose of X842”, 2 entries
- “Multiple ascending dose of X842”, 2 entries
- “Linaprazan glurate 50 mg Twice Daily (BID)”, 1 entry
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 6 studies
- Esophagitis, 2 studies
- Esophagitis, Peptic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.